Johnson & Johnson revealed Johnson & Johnson Today, Tuesday, its experimental vaccine failed to provide adequate protection against HIV in sub-Saharan Africa for young women at risk of infection, Reuters reported.
The failure of the mid-stage trial highlighted the challenges of developing a vaccine, especially for HIV, for which there are no approved vaccines yet.
Paul Stoffels, chief scientific officer of Johnson & Johnson, said: J & J In a statement: “HIV is a unique and complex virus that has long posed unprecedented challenges to vaccine development due to its ability to attack, hijack and evade the human immune system.”
According to Reuters, the study that tested the vaccine involved 2,600 women in 5 countries in South Africa, where women and girls made up more than 60% of all new HIV infections last year..
The vaccine trial, which is based on the design of the adenovirus used in Johnson’s coronavirus vaccine, has been supported J & J, by the National Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation.
Johnson said J&J The study will not continue, based on the data, study participants will be informed of the results and told whether they received a placebo or a vaccine..